MIMEDX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates MiMedx Group, Inc. Following Disclosure of FDA Letter Accusing MiMedx of Legal Violations
NEW ORLEANS--(BUSINESS WIRE)-- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. a partner at the law firm of Kahn Swick & Foti, LLC ("KSF") announces that KSF has commenced an investigation into MiMedx Group, Inc. (NAS: MDXG) .
On September 4, 2013, the Food and Drug Administration ("FDA") posted on its website an "Untitled Letter" it sent to MiMedx on August 28, which stated that MiMedx's Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing and marketing drugs that are also a biological product without a valid biologics license.
On this news, MiMedx's shares fell drastically, by over 36%.
KSF's investigation is focusing on whether MiMedx and/or its officers and directors violated state or federal securities laws.
If you have information that would assist KSF in its investigation, or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis Kahn (email@example.com) or KSF Partner Melinda Nicholson (firstname.lastname@example.org) toll free at 1-877-515-1850.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities class action and shareholder derivative litigation with offices in New York and Louisiana. KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders.
To learn more about KSF, you may visit www.ksfcounsel.com.
KEYWORDS: United States North America Louisiana
The article MIMEDX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates MiMedx Group, Inc. Following Disclosure of FDA Letter Accusing MiMedx of Legal Violations originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.